Molteni Therapeutics

Molteni Therapeutics is a clinical-stage Italian biotechnology company specializing in the development of Photodynamic Therapy (PDT) for infectious diseases and tissue repair. As a subsidiary of the Molteni Group, the company focuses on its proprietary photosensitizer, RLP068, which is designed to treat localized infections, including diabetic foot ulcers and onychomycosis. The technology utilizes a specific wavelength of light to activate the drug, generating reactive oxygen species that destroy pathogens without promoting antibiotic resistance. Molteni Therapeutics aims to address the growing global challenge of antimicrobial resistance through its innovative combination of medicinal chemistry and light-based medical devices. The company's lead programs have demonstrated efficacy in Phase 2 clinical trials, positioning it as a leader in the application of PDT for complex wound management.